

	BRASS Questionnaire Time Points (Months)																				
Domains	000	006	012	018	024	030	036	042	048	054	060	066	072	078	084	090	096	102	108	114	120
Demographics																					
Age	X		X		X		X		X		X		X		X		X		X		X
Marital Status	X		X		X		X		X		X		X		X		X		X		X
Education	X																				
# of children	X												X								
# of siblings	X																				
Birth Order			X																		
Family Hx	X	X					X						X								X
Ethnicity	X																				
Race	X																				
Social Support	X		X										X						X		
Smoking	X		X		X		X		X		X		X		X		X		X		X
Beverages	X																				
Alcohol only			X		X		X		X		X		X				X				X
General Health																					
Symptoms		X	X	X		X		X		X		X		X		X		X		X	
Co-morbidities	X		X		X		X		X		X		X		X		X		X		X
New Conditions		X		X		X		X		X		X		X		X		X		X	
Surgeries	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Dyspnoea Q	X		X		X		X		X		X		X				X		X		X
Cognitive Fxn	X		X		X		X		X		X		X				X				X
Menopause		X					X		X		X		X		X		X		X		X
Pregnancy			X		X		X		X		X		X		X		X		X		X
Oral Contracept							X														
Menstruation Hx							X														
Use of Antibiotics	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Vaccinations			X																		
Daycare/Teacher			X																		
Teeth & Gums							X						X								X
Morning Stiffness	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
COVID-19	X		X		X		X		X		X		X		X		X		X		X

BRASS Questionnaire Time Points (Months)

Domains	000	006	012	018	024	030	036	042	048	054	060	066	072	078	084	090	096	102	108	114	120
Current Medications																					
Arthritis	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Pain	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Corticosteroid	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
CAM			X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Vitamins	X		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Non-Arthritis Meds	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Alternative Providers	X		X		X		X		X		X		X		X		X		X		X
Exercise	X		X		X		X		X		X		X		X		X		X		X
Past Medications																					
All Arthritis	X		X		X		X		X		X		X		X		X		X		X
Methotrexate		X		X		X		X		X		X		X		X		X		X	
Validated Scales																					
MDHAQ ^{1,2}	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
VAS Patient Global ^{3,4}	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
VAS Fatigue Scale ^{3,4}	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
VAS Pain Scale ^{3,4}	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
SF-12 ⁵					X		X		X		X		X		X		X		X		X
MHI-5 ⁶	X		X		X						X		X		X		X		X		X
PHQ-9 ⁷			X								X		X						X		
EuroQol (EQ-5D) ⁸		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
RADAI ⁹	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Arthritis Self-Efficacy ¹⁰	X		X								X		X								
Flare Question	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
RA Concerns ¹¹			X		X	X	X	X	X	X	X	X	X	X		X		X		X	
Quality of Life Scale ^{12,13}							X														
MOS Sleep Scale ¹⁴							X		X		X				X		X		X		X
Empl/Disab/Income	X		X		X		X		X		X		X		X		X		X		X
Health Insurance					X								X		X		X				
Health Care Utilization		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Widespread Pain Index ¹⁵	X		X		X		X		X		X		X		X		X		X		X

Domains	126	132	138	144	150	156	162	168	174	180	186	192	198	204	210	216	222	228	234	240
Demographics																				
Age		X		X		X		X		X		X		X		X		X		X
Marital Status		X		X		X		X		X		X		X		X		X		X
Education																				
# of children																				
# of siblings																				
Birth Order																				
Family Hx						X										X				
Ethnicity																				
Race																				
Social Support				X						X						X				
Smoking		X		X		X		X		X		X		X		X		X		X
Beverages																				
Alcohol only				X				X				X				X				X
General Health																				
Symptoms	X		X		X		X		X		X		X		X		X		X	
Co-morbidities		X		X		X		X		X		X		X		X		X		X
New Conditions	X		X		X		X		X		X		X		X		X		X	
Surgeries	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Dyspnoea Q		X		X		X		X		X		X		X		X		X		X
Cognitive Fxn		X		X		X		X		X		X		X		X		X		X
Menopause		X		X		X		X		X		X		X		X		X		X
Pregnancy		X		X		X		X		X		X		X		X		X		X
Oral Contracept																				
Menstruation Hx																				
Use of Antibiotics	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Vaccinations																				
Daycare/Teacher																				
Teeth & Gums								X										X		
Morning Stiffness	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
COVID-19		X		X		X		X		X		X		X		X		X		X

Domains	126	132	138	144	150	156	162	168	174	180	186	192	198	204	210	216	222	228	234	240
Current Medications																				
Arthritis	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Pain	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Corticosteroid	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
CAM	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Vitamins	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Non-Arthritis Meds	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Alternative Providers		X		X		X		X		X		X		X		X		X		X
Exercise		X		X		X		X		X		X		X		X		X		X
Past Medications																				
All Arthritis		X		X		X		X		X		X		X		X		X		X
Methotrexate	X		X		X		X		X		X		X		X		X		X	
Validated Scales																				
MDHAQ ^{1,2}	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
VAS Patient Global ^{3,4}	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
VAS Fatigue Scale ^{3,4}	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
VAS Pain Scale ^{3,4}	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
SF-12 ⁵		X		X		X		X		X		X		X		X		X		X
MHI-5 ⁶		X		X		X		X		X		X		X		X		X		X
PHQ-9 ⁷				X						X						X				
EuroQol (EQ-5D) ⁸	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
RADAI ⁹	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Arthritis Self-Efficacy ¹⁰				X						X						X				
Flare Question	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
RA Concerns ¹¹	X		X		X		X		X		X		X		X		X		X	
Quality of Life Scale ^{12,13}																				
MOS Sleep Scale ¹⁴		X		X		X		X		X		X		X		X		X		X
Empl/Disab/Income		X		X		X		X		X		X		X		X		X		X
Health Insurance		X		X		X		X		X		X		X		X		X		X
Health Care Utilization	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Widespread Pain Index ¹⁵		X		X		X		X		X		X		X		X		X		X

Physician Domains	Baseline	Annual
<i>Inclusion Criteria</i>	✓	
<i>Health & Symptoms</i>		
Morning Stiffness	✓	✓
VAS	✓	✓
Infection/Oppportunistic Infections	✓	✓
Extra-Articular Manifestations	✓	✓
Co-morbidities/drug toxicities	✓	✓
28 Joint Count	✓	✓
<i>Medication Changes</i>		
Start	✓	✓
Stop/reason	✓	✓
Change/reason	✓	✓

1. Arnett, F.C., et al., *The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis*. Arthritis Rheum, 1988. **31**(3): p. 315-24.
2. Linos, A., et al., *The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality*. Am J Epidemiol, 1980. **111**(1): p. 87-98.
3. Harris, E.D., *Rheumatoid arthritis*. 1997, Philadelphia: Saunders. xxiii, 433.
4. Pincus, T., et al., *Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years*. Arthritis Rheum, 1984. **27**(8): p. 864-72.
5. Sherrer, Y.S., et al., *The development of disability in rheumatoid arthritis*. Arthritis Rheum, 1986. **29**(4): p. 494-500.
6. Callahan, L.F., et al., *Quantitative pain assessment for routine care of rheumatoid arthritis patients, using a pain scale based on activities of daily living and a visual analog pain scale*. Arthritis Rheum, 1987. **30**(6): p. 630-6.
7. Yelin, E., et al., *Work disability in rheumatoid arthritis: effects of disease, social, and work factors*. Ann Intern Med, 1980. **93**(4): p. 551-6.
8. Meenan, R.F., et al., *The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs*. Arthritis Rheum, 1978. **21**(7): p. 827-33.
9. Pincus, T., R.H. Brooks, and L.F. Callahan, *Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures*. Ann Intern Med, 1994. **120**(1): p. 26-34.
10. Stastny, P., *HLA-D and Ia antigens in rheumatoid arthritis and systemic lupus erythematosus*. Arthritis Rheum, 1978. **21**(5 Suppl): p. S139-43.
11. Young, A., et al., *Association of HLA-DR4/Dw4 and DR2/Dw2 with radiologic changes in a prospective study of patients with rheumatoid arthritis. Preferential relationship with HLA-Dw rather than HLA-DR specificities*. Arthritis Rheum, 1984. **27**(1): p. 20-5.
12. Olsen, N.J., et al., *Associations of HLA-DR4 with rheumatoid factor and radiographic severity in rheumatoid arthritis*. Am J Med, 1988. **84**(2): p. 257-64.
13. Brinkman, B.M., et al., *Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease?* Br J Rheumatol, 1997. **36**(5): p. 516-21.
14. Pincus, T., et al., *Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures*. Ann Intern Med, 1989. **110**(4): p. 259-66.
15. Scott, D.L., et al., *Long-term outcome of treating rheumatoid arthritis: results after 20 years*. Lancet, 1987. **1**(8542): p. 1108-11.
16. Mitchell, J.M., R.V. Burkhauser, and T. Pincus, *The importance of age, education, and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis*. Arthritis Rheum, 1988. **31**(3): p. 348-57.
17. Lubeck, D.P., et al., *A multicenter study of annual health service utilization and costs in rheumatoid arthritis*. Arthritis Rheum, 1986. **29**(4): p. 488-93.

18. Yelin, E. and L.A. Wanke, *An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline.* Arthritis Rheum, 1999. **42**(6): p. 1209-18.
19. Gabriel, S.E., et al., *Modeling the lifetime costs of rheumatoid arthritis.* J Rheumatol, 1999. **26**(6): p. 1269-74.
20. Nepom, G.T., et al., *HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes.* Arthritis Rheum, 1989. **32**(1): p. 15-21.
21. Wordsworth, B.P., et al., *HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region.* Proc Natl Acad Sci U S A, 1989. **86**(24): p. 10049-53.
22. Ronningen, K.S., et al., *Rheumatoid arthritis may be primarily associated with HLA-DR4 molecules sharing a particular sequence at residues 67-74.* Tissue Antigens, 1990. **36**(5): p. 235-40.
23. Gregersen, P.K., J. Silver, and R.J. Winchester, *The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis.* Arthritis Rheum, 1987. **30**(11): p. 1205-13.
24. Calin, A., J. Elswood, and P.T. Klouda, *Destructive arthritis, rheumatoid factor, and HLA-DR4. Susceptibility versus severity, a case-control study.* Arthritis Rheum, 1989. **32**(10): p. 1221-5.
25. van Zeben, D., et al., *Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study.* Arthritis Rheum, 1991. **34**(7): p. 822-30.
26. Weyand, C.M., et al., *The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis.* Ann Intern Med, 1992. **117**(10): p. 801-6.
27. Choy, E.H. and G.S. Panayi, *Cytokine pathways and joint inflammation in rheumatoid arthritis.* N Engl J Med, 2001. **344**(12): p. 907-16.
28. Singal, D.P., J. Li, and K. Lei, *Genetics of rheumatoid arthritis (RA): two separate regions in the major histocompatibility complex contribute to susceptibility to RA.* Immunol Lett, 1999. **69**(3): p. 301-6.
29. Mulcahy, B., et al., *Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis.* Am J Hum Genet, 1996. **59**(3): p. 676-83.
30. Meyer, J.M., J. Han, and G. Moxley, *Tumor necrosis factor markers show sex-influenced association with rheumatoid arthritis.* Arthritis Rheum, 2001. **44**(2): p. 286-95.
31. Hajeer, A., et al., *Tumor necrosis factor microsatellite haplotypes are different in male and female patients with RA.* J Rheumatol, 1997. **24**(1): p. 217-9.
32. Fellay, J., et al., *Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.* Lancet, 2002. **359**(9300): p. 30-6.
33. Hartmann CL, C.F., Kaufmann SH, Cliby WA, Iturria SJ, Kalli KR, Lu K, Bast B, Lillie J, Stec J et al. *Chemoprediction in Ovarian Cancer -- Genomic Approaches.* in Society of Gynecological Oncologists, 33rd Annual Meeting. 2002. Miami Beach, Florida.

34. Oestreicher, J.L., et al., *Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling*. *Pharmacogenomics J*, 2001. **1**(4): p. 272-87.
35. Petricoin, E.F., et al., *Use of proteomic patterns in serum to identify ovarian cancer*. *Lancet*, 2002. **359**(9306): p. 572-7.
36. Stucki, G., et al., *A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity*. *Arthritis Rheum*, 1995. **38**(6): p. 795-8.
37. Pincus, T., et al., *Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire*. *Arthritis Rheum*, 1983. **26**(11): p. 1346-53.
38. Ware JE, Kosinski M, Keller SD. SF-12: How to Score the SF-12 Physical and Mental Health Summary Scales. 2nd ed. Boston, MA: The Health Institute, New England Medical Center; 1995:39. Felson, D.T., et al., *American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis*. *Arthritis Rheum*, 1995. **38**(6): p. 727-35.
40. Breslow, N.E. and N.E. Day, *Statistical methods in cancer research. IARC Workshop 25-27 May 1983*. *IARC Sci Publ*, 1987(82): p. 1-406.
41. Schlesselman, J.J., *Case-Control Studies, Design, Conduct, Analysis*. Oxford University Press, New York 1982.
42. Pincus T, Swearingen C, Wolfe F. Toward a Multidimensional Health Assessment Questionnaire (MDHAQ). *Arthritis Rheum* 42;2220-30,1999.
43. Pincus T, Yazici Y, Bergman M. Development of a multi-dimensional health assessment questionnaire (MDHAQ) for the infrastructure of standard clinical care. *Clin Exp Rheumatol* 2005;23:S19-S28.
44. Rumpf HJ, Meyer C, Hapke U, John U. Screening for Mental Health: Validity of the MHI-5 using DSM-IV Axis I psychiatric disorders as a gold standard. *Psychiatry Research*. 105(3):243-53,2001.
45. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9 Validity of a Brief Depression Severity Measure. *JGIM* 16;606-13,2001.
46. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring Health-Related Quality of Life in Rheumatoid Arthritis: Validity, Responsiveness and Reliability of EuroQol (EQ-5D). *British J Rheum*. 35;551-59,1997.
47. Stucki, G, Liang M, Stucki S, Bruhlmann P, Michel BA. A Self-Administered Rheumatoid Arthritis Disease Activity Index (RADAI) for Epidemiological Research. *Psychometric properties and correlation with parameters of disease activity*. *Arthritis Rheum*. 38;795-98,1995.
48. Lorig K, Chastain RL, Ung E, Shoor S, Holman HR. Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis. *Arthritis Rheum*. 32;37-44,1989.
49. Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, Kirwan J. *Rheumatology Outcomes: The Patient's Perspective*. *J Rheum*. April 2003 30(4);880-83.
50. Flanagan JC. A research approach to improving our quality of life. *AM Psychol*. 1078;33:138-47.

51. Hays RD, Steward AL. Sleep Measures. Measuring functioning and well-being: The Medical Outcomes Study Approach. 235-259. Durham, NC: Duke University Press.
52. Wolfe F. Pain extent and diagnosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. *J Rheumatol*. 2003 Feb;30(2):69-78.
53. Berkman, Syme. Social Networks, host resistance and mortality: a nine year follow-up study of Alameda County residents. *Am J Epidemiol*. 109;186-204;1979.